Driving Precision Medicine Through Molecular Testing in NSCLC

EP: 1.Treatment Approaches for Early-Stage Lung Cancer

Now Viewing

EP: 2.Driving Precision Medicine Through Molecular Testing in NSCLC

EP: 3.Neoadjuvant/Perioperative Immunotherapy in NSCLC

EP: 4.Referral of Early-Stage NSCLC to Multidisciplinary Teams

EP: 5.Neoadjuvant, Adjuvant, and Perioperative Options in NSCLC

EP: 6.Updates in CheckMate-816 From ESMO 2023

EP: 7.AEGEAN Trial: Perioperative Approach in NSCLC

EP: 8.Latest From the NEOTORCH Trial & KEYNOTE-671 Trial

EP: 9.CheckMate-77T Trial Results From ESMO 2023

EP: 10.Treatment Decision Making by Stage for Resectable NSCLC

EP: 11.The Emerging Role of ctDNA in NSCLC Management

EP: 12.Addressing Gaps in Care for Non-Small Cell Lung Cancer

This is a video synopsis/summary of a Precision Medicine featuring Patrick Forde, MBBCh, and Tina Cascone, MD, PhD.

Forde and Cascone discuss the evolution of molecular testing for patients with non–small cell lung cancer (NSCLC). Over the past decade, the quantity and extent of testing have rapidly increased. Previously, testing focused mainly on patients with advanced nonsquamous cancers for actionable genomic alterations such as EGFR and ALK. Currently, it is recommended to test virtually all patients with advanced disease for molecular aberrations that can inform targeted therapy decisions, using broad-based next-generation sequencing per National Comprehensive Cancer Network guidelines. Molecular testing is also considered for early-stage disease due to implications for patients with EGFR or ALK alterations who may be eligible for adjuvant targeted therapy.

The role of PD-L1 in informing neoadjuvant and perioperative treatment decisions is also discussed. The magnitude of benefit with immunotherapy approaches is greater according to PD-L1 expression, with a deeper benefit in patients whose tumors have a PD-L1 expression of 50% or higher. However, PD-L1 status should not be the sole factor influencing treatment decisions, as there may be benefit in patients whose tumors do not express PD-L1. Other factors, including stage, combine with PD-L1 to inform patient disposition to neoadjuvant, perioperative, or adjuvant treatment.

Video synopsis is AI-generated and reviewed by Targeted Oncology™ editorial staff.